http://www.nitrc.org/forum/forum.php?forum_id=8107 <table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&amp;cmd=Link&amp;LinkName=pubmed_pubmed&amp;from_uid=29255671">Related Articles</a></td></tr></table> <p><b>Molecular and functional PET-fMRI measures of placebo analgesia in episodic migraine: Preliminary findings.</b></p> <p>Neuroimage Clin. 2018;17:680-690</p> <p>Authors: Linnman C, Catana C, Petkov MP, Chonde DB, Becerra L, Hooker J, Borsook D</p> <p>Abstract<br/> Pain interventions with no active ingredient, placebo, are sometimes effective in treating chronic pain conditions. Prior studies on the neurobiological underpinnings of placebo analgesia indicate endogenous opioid release and changes in brain responses and functional connectivity during pain anticipation and pain experience in healthy subjects. Here, we investigated placebo analgesia in healthy subjects and in interictal migraine patients (n = 9) and matched healthy controls (n = 9) using 11C-diprenoprhine Positron Emission Tomography (PET) and simultaneous functional Magnetic Resonance Imaging (fMRI). Intravenous saline injections (the placebo) led to lower pain ratings, but we did not find evidence for an altered placebo response in interictal migraine subjects as compared to healthy subjects.<br/> </p><p>PMID: 29255671 [PubMed - in process]</p> en-us Copyright 2000-2026 NITRC OSI Sun, 03 May 2026 16:25:55 GMT http://blogs.law.harvard.edu/tech/rss NITRC RSS generator